About Us
Built With Purpose
Founded in 2022, Cellergy Pharma is a privately held biotechnology company that is developing novel CAR T cell products for treating severe atopic allergic diseases. The company is at the forefront of moving CAR T cells beyond the treatment of cancer, to the treatment of diseases caused by the immune system. Cellergy’s patented EMPD and FcεRI chimeric antigen receptors target the cells that produce immunoglobulin E, the cause of all atopic allergic diseases.
Impact-Driven Research
At Cellergy Pharma, our mission is to cure severe allergic diseases including uncontrollable severe allergic asthma, and severe food allergy.
Redefining Possibilities
We have developed novel CAR T cells that target and eliminate the source of allergic disease - IgE-producing cells.